Skip to main content
Top
Published in: Calcified Tissue International 1/2003

01-07-2003 | Laboratory Investigations

Osteopontin Facilitates Bone Resorption, Decreasing Bone Mineral Crystallinity and Content During Calcium Deficiency

Authors: S. A. Shapses, M. Cifuentes, L. Spevak, H. Chowdhury, J. Brittingham, A. L. Boskey, D. T. Denhardt

Published in: Calcified Tissue International | Issue 1/2003

Login to get access

Abstract

Osteopontin null-mice were previously shown to have bones containing more mineral and larger mineral crystals. These bones were independently seen to be resistant to ovariectomy-induced remodeling. To separate the physicochemical effects of osteopontin, which is an in vitro inhibitor of mineral crystal formation and growth, from effects of osteopontin on in vivo bone remodeling, this study examined mature (5-month-old) osteopontin-null (Opn−/−) and wildtype (WT) mice given a calcium-deficient diet. Biochemical parameters were measured during 4 weeks of Ca deficiency, followed by 1 week of refeeding adequate Ca. Ca deficiency caused a transiently greater rise in bone resorption in WT than Opn−/− mice (P = 0.01), whereas only the Opn−/− mice tended to increase Ca absorption (P = 0.08), yet both groups showed elevated levels of parathyroid hormone (PTH) (P < 0.001). The rise in markers of bone formation due to Ca deficiency was similar in both groups during Ca deficiency. Fourier transform infrared microspectroscopy assessed mineral properties at 20 µm spatial resolution in different anatomic regions of the bone. The Ca-deficient Opn−/− animals had slightly increased mineral content as compared to the WT, and there was a significant increase in the mineral content of older (endosteal) bone, implying that osteoclast recruitment was impaired. Crystallinity in the Ca-deficient Opn−/− bones was increased relative to the Ca-deficient WT at all sites except adjacent to the periosteum (younger mineral). These data suggest that osteopontin has both a physicochemical effect (inhibiting crystal growth and crystal proliferation) and a role in osteoclast recruitment, and in its absence, extraskeletal organs maintain calcium homeostasis.
Literature
1.
go back to reference Denhardt, DT, Noda, M, O’Regan, AW, Pavlin, D, Berman, JS 2001Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.J Clin Invest10710551061PubMed Denhardt, DT, Noda, M, O’Regan, AW, Pavlin, D, Berman, JS 2001Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.J Clin Invest10710551061PubMed
2.
go back to reference Butler, WT, Ridall, AL, McKee, MD 1996Osteopontin.Bilezikian, JPRaisz, LGRodan, GA eds. Principles of bone biology.Academic Press,San Diego,167181 Butler, WT, Ridall, AL, McKee, MD 1996Osteopontin.Bilezikian, JPRaisz, LGRodan, GA eds. Principles of bone biology.Academic Press,San Diego,167181
3.
go back to reference Boskey, AL, Maresca, M, Ullrich, W, Doty, SB, Butler, WT, Prince, CW 1993Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel.Bone Miner22147159PubMed Boskey, AL, Maresca, M, Ullrich, W, Doty, SB, Butler, WT, Prince, CW 1993Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel.Bone Miner22147159PubMed
4.
go back to reference Hunter, GK, Kyle, CL, Goldberg, HA 1994Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation.Biochem J300723728PubMed Hunter, GK, Kyle, CL, Goldberg, HA 1994Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation.Biochem J300723728PubMed
5.
go back to reference Stubbs III, JT 1996Generation and use of recombinant human bone sialoprotein and osteopontin for hydroxyapatite studies.Connect Tissue Res35393399PubMed Stubbs III, JT 1996Generation and use of recombinant human bone sialoprotein and osteopontin for hydroxyapatite studies.Connect Tissue Res35393399PubMed
6.
go back to reference Hunter, GK, Hauschka, PV, Poole, AR, Rosenberg, LC, Goldberg, HA 1996Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins.Biochem J3175964PubMed Hunter, GK, Hauschka, PV, Poole, AR, Rosenberg, LC, Goldberg, HA 1996Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins.Biochem J3175964PubMed
7.
go back to reference Boskey, AL 1995Osteopontin and related phosphorylated sialoproteins: effects on mineralization.Ann NY Acad Sci760249256PubMed Boskey, AL 1995Osteopontin and related phosphorylated sialoproteins: effects on mineralization.Ann NY Acad Sci760249256PubMed
8.
go back to reference Wesson, JA, Worcester, EM, Wiessner, JH, Mandel, NS, Kleinman, JG 1998Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules.Kidney Int53952957CrossRefPubMed Wesson, JA, Worcester, EM, Wiessner, JH, Mandel, NS, Kleinman, JG 1998Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules.Kidney Int53952957CrossRefPubMed
9.
go back to reference Giachelli, CM, Steitz, S 2000Osteopontin: a versatile regulator of inflammation and biomineralization.Matrix Biol19615622CrossRefPubMed Giachelli, CM, Steitz, S 2000Osteopontin: a versatile regulator of inflammation and biomineralization.Matrix Biol19615622CrossRefPubMed
10.
go back to reference Proudfoot, D, Skepper, JN, Shanahan, CM, Weissberg, PL 1998Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression.Arterioscler Thromb Vasc Biol18379388 Proudfoot, D, Skepper, JN, Shanahan, CM, Weissberg, PL 1998Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression.Arterioscler Thromb Vasc Biol18379388
11.
go back to reference Lieske, JC, Hammes, MS, Hoyer, JR, Toback, FG 1997Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals.Kidney Int51679686PubMed Lieske, JC, Hammes, MS, Hoyer, JR, Toback, FG 1997Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals.Kidney Int51679686PubMed
12.
go back to reference Beck Jr, GR, Zerler, B, Moran, E 2000Phosphate is a specific signal for induction of osteopontin gene expression.Proc Natl Acad Sci USA.9783528357CrossRefPubMed Beck Jr, GR, Zerler, B, Moran, E 2000Phosphate is a specific signal for induction of osteopontin gene expression.Proc Natl Acad Sci USA.9783528357CrossRefPubMed
13.
go back to reference Rittling, SR, Matsumoto, HN, McKee, MD, et al. 1998Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.J Bone Miner Res1311011111PubMed Rittling, SR, Matsumoto, HN, McKee, MD,  et al. 1998Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.J Bone Miner Res1311011111PubMed
14.
go back to reference Liaw, L, Birk, DE, Ballas, CB, Whitsitt, JS, Davidson, JM, Hogan, BL 1998Altered wound healing in mice lacking a functional osteopontin gene (suppl).J Clin Invest10114681478 Liaw, L, Birk, DE, Ballas, CB, Whitsitt, JS, Davidson, JM, Hogan, BL 1998Altered wound healing in mice lacking a functional osteopontin gene (suppl).J Clin Invest10114681478
15.
go back to reference Boskey, AL, Spevak, L, Paschalis, E, Doty, SB, McKee, MD 2002Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone.Calcif Tissue Int70145154CrossRef Boskey, AL, Spevak, L, Paschalis, E, Doty, SB, McKee, MD 2002Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone.Calcif Tissue Int70145154CrossRef
16.
go back to reference Yoshitake, H, Rittling, SR, Denhardt, DT, Noda, M 1999Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.Proc Natl Acad Sci USA9681568160CrossRefPubMed Yoshitake, H, Rittling, SR, Denhardt, DT, Noda, M 1999Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.Proc Natl Acad Sci USA9681568160CrossRefPubMed
17.
go back to reference Ihara, H, Denhardt, DT, Furuya, K, et al. 2001Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.J Biol Chem2761306513071CrossRefPubMed Ihara, H, Denhardt, DT, Furuya, K,  et al. 2001Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.J Biol Chem2761306513071CrossRefPubMed
18.
go back to reference Ishijima, M, Rittling, SR, Yamashita, T, et al. 2001Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.J Exp Med193399404CrossRefPubMed Ishijima, M, Rittling, SR, Yamashita, T,  et al. 2001Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.J Exp Med193399404CrossRefPubMed
19.
go back to reference Denhardt, DT, Noda, M 1998Osteopontin expression and function: role in bone remodeling.J Cell Biochem (suppl)30–3192102 Denhardt, DT, Noda, M 1998Osteopontin expression and function: role in bone remodeling.J Cell Biochem (suppl)30–3192102
20.
go back to reference Kalu, DN, Chen, C 1999Ovariectomized murine model of postmenopausal calcium malabsorption.J Bone Miner Res14593601PubMed Kalu, DN, Chen, C 1999Ovariectomized murine model of postmenopausal calcium malabsorption.J Bone Miner Res14593601PubMed
21.
go back to reference Stegemann, H, Stalder, K 1967Determination of hydroxyproline.Clin Chim Acta18267273PubMed Stegemann, H, Stalder, K 1967Determination of hydroxyproline.Clin Chim Acta18267273PubMed
22.
go back to reference Farndale, RW, Sayers, CA, Barrett, AJ 1982A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures.Connect Tissue Res9247248PubMed Farndale, RW, Sayers, CA, Barrett, AJ 1982A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures.Connect Tissue Res9247248PubMed
23.
go back to reference Aparicio, S, Doty, SB, Camacho, NP, Paschalis, EP, Spevak, L, Mendelsohn, R, Boskey, AL 2002Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy.Calcif Tissue Int70422429PubMed Aparicio, S, Doty, SB, Camacho, NP, Paschalis, EP, Spevak, L, Mendelsohn, R, Boskey, AL 2002Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy.Calcif Tissue Int70422429PubMed
24.
go back to reference Gadaleta, SJ, Paschalis, EP, Betts, F, Mendelsohn, R, Boskey, AL 1996Fourier transform infrared spectroscopy of the solution-mediated conversion of amorphous calcium phosphate to hydroxyapatite: new correlations between X-ray diffraction and infrared data.Calcif Tissue Int58916CrossRefPubMed Gadaleta, SJ, Paschalis, EP, Betts, F, Mendelsohn, R, Boskey, AL 1996Fourier transform infrared spectroscopy of the solution-mediated conversion of amorphous calcium phosphate to hydroxyapatite: new correlations between X-ray diffraction and infrared data.Calcif Tissue Int58916CrossRefPubMed
25.
go back to reference Paschalis, EP, Betts, F, DiCarlo, E, Mendelsohn, R, Boskey, AL 1997FTIR microspectroscopic analysis of normal human cortical and trabecular bone.Calcif Tissue Int61480486CrossRefPubMed Paschalis, EP, Betts, F, DiCarlo, E, Mendelsohn, R, Boskey, AL 1997FTIR microspectroscopic analysis of normal human cortical and trabecular bone.Calcif Tissue Int61480486CrossRefPubMed
26.
go back to reference Noiri, E, Dickman, K, Miller, F, et al. 1999Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene.Kidney Int567482CrossRefPubMed Noiri, E, Dickman, K, Miller, F,  et al. 1999Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene.Kidney Int567482CrossRefPubMed
27.
go back to reference Kalu, DN, Orhii, PB 1999Calcium absorption and bone loss in ovariectomized rats fed varying levels of dietary calcium.Calcif Tissue Int657377CrossRefPubMed Kalu, DN, Orhii, PB 1999Calcium absorption and bone loss in ovariectomized rats fed varying levels of dietary calcium.Calcif Tissue Int657377CrossRefPubMed
28.
go back to reference Talbott, SM, Shapses, SA 1998Energy and calcium induced alterations in bone turnover and density in young and aged female rats.J Nutr128640645PubMed Talbott, SM, Shapses, SA 1998Energy and calcium induced alterations in bone turnover and density in young and aged female rats.J Nutr128640645PubMed
29.
go back to reference Murray, EJ, Murray, SS, Grisanti, M, Duarte, ME, Urist, MR 1997Effect of low dietary calcium on bone metabolism in the SENCAR mouse.J Orthop Res15585592PubMed Murray, EJ, Murray, SS, Grisanti, M, Duarte, ME, Urist, MR 1997Effect of low dietary calcium on bone metabolism in the SENCAR mouse.J Orthop Res15585592PubMed
Metadata
Title
Osteopontin Facilitates Bone Resorption, Decreasing Bone Mineral Crystallinity and Content During Calcium Deficiency
Authors
S. A. Shapses
M. Cifuentes
L. Spevak
H. Chowdhury
J. Brittingham
A. L. Boskey
D. T. Denhardt
Publication date
01-07-2003
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2003
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-1090-x

Other articles of this Issue 1/2003

Calcified Tissue International 1/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.